Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Enforma settlement

This article was originally published in The Tan Sheet

Executive Summary

Infomercial producer Modern Interactive Technology has settled FTC charges alleging the firm played an "active role" in writing, editing and producing infomercials for the Enforma System of weight-loss products, the commission announces March 1. The company and principals Mark Levine and David Richmond originally were charged in August 2000, shortly after Enforma Natural Products was charged with making unsubstantiated ad claims for Fat Trapper and Exercise in a Bottle, which comprise the system. The settlement prohibits the firm from "misrepresenting the profession, expertise, training, education, experience, or qualifications of any person who advertises, promotes, or endorses any product, service or program." Enforma Natural Products also recently settled FTC charges in an agreement that bars the company from future marketing of weight-loss products (1"The Tan Sheet" Jan. 24, 2005, p. 12)...

You may also be interested in...

Weight-Loss Product Manufacturers Receive FTC Rebuke

A Federal Trade Commission settlement with the makers of Exercise in a Bottle and Fat Trapper barring the firms from marketing weight-loss products in the future is an example of the agency's willingness to deliver severe punishments against repeat offenders

Keeping Track: US FDA's Rejection Of First RMAT BLA Blemishes Otherwise Positive Week Of Non-Oncology News

The latest non-oncology drug development news and highlights from our US FDA Performance Tracker.

FDA Commissioner Nominee Hahn Advances To Full Senate, Despite Some Dems’ Reservations

Stephen Hahn, the Trump administration’s nominee to lead the US FDA, has been approved by the Senate Health, Education, Labor and Pensions (HELP) Committee, with some “no votes” from Democratic senators in leadership positions, and is expected to be considered by the full Senate this week.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts